ImageneBio
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Immunology
ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients who have immunological, autoimmune and inflammatory diseases. IMG-007 is our next-generation investigational anti-OX40 monoclonal antibody.
Company HQ City:
San Diego
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2025
Lead Product in Development:
IMG-007
CEO
Kristin Yarema, Ph.D.
Development Phase of Lead Product
Phase II
Exchange
Nasdaq
Ticker
IMA
When you expect your next catalyst update?
2027
What is your next catalyst (value inflection) update?
Ph2b in atopic dermatitis primary data readout
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}